Tagged with EG

Pharma Legal Handbook Marketing, manufacturing, packaging & labeling, advertising in Japanese Pharma – a comprehensive legal overview. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract from The Pharma Legal Handbook: Japan, available to purchase here for GBP 149.   1. What is the authorization process for…

Pharma Legal Handbook The low-down on the situation regarding preclinical & clinical trial requirements in Japanese Pharma. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract from The Pharma Legal Handbook: Japan, available to purchase here for GBP 149.   1. Are clinical trials required to…

Pharma Legal Handbook An intro to the legal situation for regulatory, pricing and reimbursement in Japan. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract from The Pharma Legal Handbook: Japan, available to purchase here for GBP 149.   1. What are the regulatory authorities…

Egypt Egypt’s largest pharmaceutical manufacturer by units, EIPICO, plans to diversify its production capacity by building the country’s first biological & biosimilar production plant. Not only that, the company is leading the change towards localization and local production of APIs. Founded in 1980, EIPICO is currently the number one company in…

Egypt The chairman of EIPICO – Egypt’s largest pharma company by units –, Dr Ahmed Kelani, outlines the company’s ambitious growth strategy, which includes the construction of the first biological & biosimilar production plant in Egypt. The plant is expected to commence production at the end of 2023 and would become…

South Korea ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and medical aesthetics. He walks us through ExoCoBio’s exosome-based finished product line as well as its promising preclinical findings not just…

Italy EG STADA’s General Manager & Managing Director Italy, Salvatore Butti, explains the company’s strong heritage in generics, the solid presence it is developing in consumer healthcare with new acquisitions from GSK and Sanofi, and its biosimilar and specialties market inroads.  In addition, he tells us about the STADA Health Report,…

Spain The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict containment measures, the Europe’s economy went into the greatest recession since the Second World War during the first half of 2020. To…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…

Egypt The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies are rushing in under the umbrella of the universal healthcare law, and the role of France in helping Egypt grow.…

Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…